[HTML][HTML] Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

SA Guler, L Ebner, C Aubry-Beigelman… - European respiratory …, 2021 - Eur Respiratory Soc
Background The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing
global healthcare challenge. Up to one-third of hospitalised patients develop severe …

Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair

TK Geiser, BI Kazmierczak, LK Garrity‐Ryan… - Cellular …, 2001 - Wiley Online Library
The nosocomial pathogen Pseudomonas aeruginosa causes clinical infection in the setting
of pre‐existing epithelial tissue damage, an association that is mirrored by the increased …

Frailty assessment for COVID-19 follow-up: a prospective cohort study

I Müller, M Mancinetti, A Renner… - BMJ open …, 2022 - bmjopenrespres.bmj.com
Background The Clinical Frailty Scale (CFS) is increasingly used for clinical decision making
in acute care but little is known about frailty after COVID-19. Objectives To investigate frailty …

Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: a randomized controlled crossover trial

SA Guler, C Clarenbach, M Brutsche… - Annals of the …, 2021 - atsjournals.org
Rationale: Patients with idiopathic pulmonary fibrosis (IPF) frequently suffer from chronic
cough that is difficult to treat, which substantially affects their quality of life. Azithromycin has …

[HTML][HTML] Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls

K Krempaska, S Barnowski, J Gavini, N Hobi… - Respiratory …, 2020 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease without a cure
and new drug strategies are urgently needed. Differences in behavior between diseased …

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts

C Machahua, SA Guler, MP Horn… - BMJ open …, 2021 - bmjopenrespres.bmj.com
Background Non-invasive biomarkers for the assessment of disease severity in idiopathic
pulmonary fibrosis (IPF) are urgently needed. Calprotectin belongs to the S-100 proteins …

Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis

S Guler, AC Sarbu, O Stalder, Y Allanore, V Bernardino… - thorax, 2023 - thorax.bmj.com
Background Systemic sclerosis (SSc) is a heterogeneous disease with frequently associated
interstitial lung disease (SSc-ILD). We aimed to determine the prognostic potential of …

[HTML][HTML] Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study

SA Guler, C Machahua, TK Geiser, G Kocher… - Respiratory …, 2022 - Springer
Background Dehydroepiandrosterone (DHEA) is a precursor sex hormone with antifibrotic
properties. The aims of this study were to investigate antifibrotic mechanisms of DHEA, and …

Activity of pulmonary edema fluid interleukin-8 bound to α2-macroglobulin in patients with acute lung injury

AK Kurdowska, TK Geiser, SM Alden… - … of Physiology-Lung …, 2002 - journals.physiology.org
The formation of α2-macroglobulin (α2-M)/interleukin-8 (IL-8) complexes may influence the
biological activity of IL-8 and the quantitative assessment of IL-8 activity. Therefore, in this …

[HTML][HTML] Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case–control study

SA Guler, E Wohlfarth, S Berezowska, TK Geiser… - Respiratory …, 2021 - Springer
Background The differential diagnosis fibrotic hypersensitivity pneumonitis (HP) versus
idiopathic pulmonary fibrosis (IPF) is important but challenging. Recent diagnostic …